475 Results

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Hyman
    Hyman
  4. Kris
    Kris
  5. Arcila
    Arcila
  6. Riely
    Riely
  7. Li
    Li
  8. Rudin
    Rudin
  9. Offin
    Offin
  10. Benayed
    Benayed

Groups

  1. Department of Medicine (475)
  2. Solid Tumor Oncology Division (475)
  3. Thoracic Oncology (475)
  4. GSK Faculty (152)
  5. Human Oncology and Pathogenesis Program (129)
  6. Early Drug Development Service (101)
  7. Sloan Kettering Institute Postdocs (75)
  8. Radiology, Department of (59)
  9. Gynecologic Medicine Service (58)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (57)
  1. "Alexander Drilon"
  2. "Solid Tumor Oncology Division"
  3. "Department of Medicine"
Formats
  1. Meeting Abstract (286)
  2. Journal Article (167)
  3. Review (13)
  4. Editorial (4)
  5. Book Section (2)
  6. Book Whole (1)
  7. Guidelines (1)
  8. Research Letter (1)
Groups
  1. Department of Medicine (475)
  2. Solid Tumor Oncology Division (475)
  3. Thoracic Oncology (475)
  4. GSK Faculty (152)
  5. Human Oncology and Pathogenesis Program (129)
  6. Early Drug Development Service (101)

More Groups

People
  1. Alexander Drilon (475)
  2. Marc Ladanyi (104)
  3. David Hyman (77)
  4. Mark Kris (75)
  5. Maria Arcila (69)
  6. Gregory Riely (57)

More People

Years
  1. 2022 (75)
  2. 2021 (76)
  3. 2020 (80)
  4. 2019 (76)
  5. 2018 (55)
  6. 2017 (33)

More Years

Publications
  1. Journal of Clinical Oncology (106)
  2. Annals of Oncology (70)
  3. Journal of Thoracic Oncology (60)
  4. Clinical Cancer Research (28)
  5. Oncology Research and Treatment (20)
  6. Cancer Research (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (122)
  2. Elsevier Inc. (84)
  3. Oxford University Press (83)
  4. American Association for Cancer Research (60)
  5. Nature Publishing Group (23)
  6. S. Karger AG (20)

More Publishers

Results (475)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Durability of efficacy with selpercatinib in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Drillon, A. E.; Subbiah, V.; Gautschi, O.; Tomasini, P.; De Braud, F. G.; Solomon, B.; Tan, D. S. W.; Alonso, G.; Wolf, J.; Park, K.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update
    Meeting Abstract

    Sherman, E.; Wirth, L.; Shah, M.; Cabanillas, M.; Robinson, B.; Italiano, A.; Laskin, J.; Subbiah, V.; Drilon, A.; Wright, J.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors
    Meeting Abstract

    Perreault, S.; Drilon, A.; Lassen, U. N.; Geoerger, B.; Nysom, K.; Øra, I.; Gavrilovic, I. T.; Norenberg, R.; Bernard-Gauthier, V.; De La Cuesta, E.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Genomic alterations in ALK fusion-positive non-small cell lung cancer (NSCLC) patients with brain metastases
    Meeting Abstract

    Eichholz, J.; Miao, E.; Lebow, E.; Walch, H.; Flynn, J.; Zhang, Z.; Hubbeling, H.; Beal, K.; Moss, N.; Yu, K.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial
    Meeting Abstract

    Kroiss, M.; Sherman, E. J.; Wirth, L. J.; Cabanillas, M. E.; Robinson, B.; Subbiah, V.; Drilon, A. E.; Godbert, Y.; Fasnacht, N.; Soldatenkova, V.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study
    Meeting Abstract

    Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, C.; Shim, B. Y.; Han, J. Y.; Drilon, A. E.; Lena, H.; Gomez, J. E.; Gray, J. E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study
    Meeting Abstract

    Drilon, A. E.; Chan, J.; Sands, J.; Tan, D. S. W.; Weiss, J.; Solomon, B.; Kim, Y. J.; Johnson, M. L.; Puri, T.; Sarno, M. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
    Meeting Abstract

    Hong, D. S.; Tahara, M.; Baik, C.; Bauman, J. R.; Gilbert, J.; Brose, M. S.; Grilley-Olson, J. E.; Patil, T.; McDermott, R.; Raez, L. E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
    Meeting Abstract

    McDermott, R. S.; van Tilburg, C.; Lin, J. J.; Kummar, S.; Tan, D. S. W.; Albert, C. M.; Berlin, J. D.; Lassen, U. N.; Doz, F.; Geoerger, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset
    Meeting Abstract

    Italiano, A.; Drilon, A. E.; Shen, L.; Hong, D. S.; van Tilburg, C.; Tan, D. S. W.; Lin, J. J.; Kummar, S.; Doz, F.; Geoerger, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save